Organization | Groupe D'Etude des Tumeurs Uro-Genitales

Groupe D'Etude des Tumeurs Uro-Genitales Report issue

Academic/Hospital Phase 2 Phase 3

Founded: Paris France (1994)

Organization Overview

First Clinical Trial

2001

NCT00022191

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2006

Timeline

NOW

Now

Active Ingredients

Drugs in Phase 3 Trials (7)

cisplatin (platinol) (3 trials)

doxorubicin (Doxil) (1 trial)

gemcitabine (gemzar) (3 trials)

naltrexone (revia) (1 trial)

paclitaxel (taxol) (1 trial)

sargramostim (leukine) (1 trial)

vinblastine (velban) (1 trial)

Drugs in Phase 2 Trials (4)

etoposide (vepesid) (1 trial)

mitoxantrone (novantrone) (1 trial)

prednisone (meticorten) (1 trial)

vinorelbine (navelbine) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Carcinoma (Phase 3)

Carcinoma, Transitional Cell (Phase 3)

Kidney Neoplasms (Phase 3)

Prostatic Neoplasms (Phase 2)

Ureteral Neoplasms (Phase 3)

Urethral Neoplasms (Phase 3)

Urinary Bladder Neoplasms (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 4
# of Trial APIs: 11